Zephyrm Biotechnologies Co., Ltd. (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) on September 30, 2024, with the intention to list on the Main Board, with CICC acting as the sole sponsor.
Established in 2017, Zephyrm Bio, a clinical-stage biopharmaceutical company, is focused on the development of innovative cell therapy products derived from pluripotent stem cells (“PSCs”) for the treatment of a variety of diseases. As a pioneer in China and globally in the development of PSC-derived cell therapy products, according to Frost & Sullivan, Zephyrm Bio is one of the first companies in China to receive approval for a new drug clinical trial application (“IND”) for PSC-derived cell therapy and the only company in China with multiple PSC-derived cell therapy assets currently in Phase II clinical trials.
Currently, Zephyrm Bio has developed a pluripotent stem cell-derived cell therapy product development platform (“PROF”), which consists of three independent yet integrated technical platforms: the Pluripotent Stem Cell Seed Cell Platform (“PROF-seed”), the Key Functional Cell Screening and Development Platform (“PROF-function”), and the Prescription Optimization Platform (“PROF-formulator”).
Leveraging its integrated technical platform, Zephyrm Bio has developed a product pipeline consisting of four types of PSC-derived cell therapy products, covering seven indications, including Acute Exacerbation of Interstitial Lung Disease (“AE-ILD”), Acute Graft-Versus-Host Disease (“aGVHD”), Meniscal Injury, Acute Respiratory Distress Syndrome (“ARDS”), Parkinson’s Disease, Dry Age-Related Macular Degeneration (“AMD”), and Corneal Endothelial Decompensation.
Specifically, Zephyrm Bio’s product portfolio includes core product ZH901 and key products ZH903, ZH902, and ZH906. As of September 21, 2024, Zephyrm Bio’s core product ZH901 has entered Phase II clinical trials and is being studied for the treatment of AE-ILD, aGVHD, Meniscal Injury, and ARDS; ZH903 and ZH902 are currently undergoing Investigator-Initiated Trials (“IIT”) for the treatment of Parkinson’s Disease and Dry AMD, respectively; ZH906 is used for the treatment of Corneal Endothelial Decompensation and is currently in the preclinical stage.
Since its establishment, Zephyrm Bio has received investments from well-known institutions such as Zhongke Chuangxing, Jianxin (Beijing) Fund, Yueke Mother Fund, Guoke Jiahe, Zhongke Xinchan, Zhongshan Venture Capital, Zhongshan Torch, Bencao Capital, Zhenji Capital, Shaanxi Investment Growth Fund, Beijing Huairou Science City, and Walken Capital.
In its prospectus, Zephyrm Bio stated that the net proceeds from the IPO will mainly be used to fund the research, development, and registration of the core product ZH901; to fund the research and development of products other than ZH901; to fund the construction of the Zhongshan factory and the establishment of commercialization capabilities; and for working capital and other general corporate purposes.- Flcube.com
